Publications

Research Summary

Overview

The research activity of Stefano Denicolai regards the management of innovation and technology. His recent works investigate if and how the investment in intangible assets (IA) - especially knowledge assets, such as patents or copyright - impacts on the firm... View Details

Keywords: Innovation Management; International Entrepreneurship; Intangible Assets; Open Innovation; Innovation and Management; Entrepreneurship; Competitive Strategy; Technology Industry; Technology Industry; Technology Industry; Technology Industry

September 2013 (Revised August 2014)
Case

Claritas Genomics

By: Robert F. Higgins and Matthew Preble

Claritas Genomics was formed in January 2013 when BCH spun out its Genetics Diagnostic Lab into a fully commercial entity. Claritas offered over 100 genomic tests to detect a range of conditions, including autism and intellectual disabilities, and was developing new... View Details

February 2021
Case

Digital Manufacturing at Amgen

By: Shane Greenstein, Kyle R. Myers and Sarah Mehta

This case discusses efforts made by biotechnology (biotech) company Amgen to introduce digital technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics—or therapeutics made from living cells—is... View Details

May 2006 (Revised June 2006)
Case

Codon Devices

By: Joseph B. Lassiter III and David Kiron

In December 2005, 40-year-old John Danner was about to make his first presentation to the board of directors of Codon Devices, a one-year-old biotechnology start-up based in Cambridge, Massachusetts. After a month as the company's CEO, Danner was prepared to lay out... View Details

Keywords: Strategic Planning; Venture Capital; Intellectual Property; Governing and Advisory Boards; Genetics; Competitive Advantage; Science-Based Business; Business Startups; Growth and Development Strategy; Biotechnology Industry; Cambridge

Find at Harvard

March 1996
Case

Erox Corporation: Leverage Marketing

Erox Corp. is a biotechnology start-up that creates products containing synthetic human pheromones. It was founded in 1989, went public in 1993, and brought in a turnaround team in 1994. Sales ramped from $110,000 in 1993 to over $1 million in 1994, with prospects for... View Details

Keywords: Marketing Communications; Entrepreneurship; Biotechnology Industry

March 1992
Case

Amgen, Inc.: Planning the Unplannable

By: Nitin Nohria

By the early 1990s, Amgen--a pharmaceutical company started little over a decade ago as Applied Molecular Genetics--was within range of becoming a billion-dollar company. With two extremely successful biotechnology drugs on the market, Amgen stood as the largest and... View Details

Keywords: Growth and Development Strategy; Strategic Planning; Success; Risk and Uncertainty; Pharmaceutical Industry

February 2003
Article

Which Ties Matter When? The Contingent Effects of Interorganizational Partnerships on IPO Success

By: Ranjay Gulati and M. Higgins

This paper investigates the contingent value of interorganizational relationships at the time of a young firm's initial public offering (IPO). We compare the signaling value to young firms of having ties with two types of interorganizational partnerships: endorsement... View Details

Keywords: Interorganizatonal Relationships; Networks; Venture Capital; Initial Public Offering; Entrepreneurship; Biotechnology Industry

Find at Harvard

April 2002
Case

In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen

By: Juan Enriquez-Cabot, Gary P. Pisano and Gaye Bok

Biogen is a successful biotech company facing a critical juncture. CEO John Mullen ponders how technological changes introduced into the research function will shape larger corporate decisions. This world in which biotechnology companies operated had changed... View Details

Keywords: Change; Decisions; Product Development; Research and Development; Expansion; Technology; Biotechnology Industry

07 Aug 2000
Research & Ideas

The Business of Biotech

nervous. Several days before the Biotechnology Industry Organization's (BIO) annual conference convened this past March in Boston, opponents held their own forum of seminars and talks under the banner of... View Details

Keywords: by Julia Hanna; Biotechnology; Biotechnology; Biotechnology

Article

What to Know About Locating in a Cluster

By: Willy C. Shih and Sen Chai

As a study of two industry clusters in Denmark shows, factors that can make clusters attractive—easy people movement and knowledge spillovers—can also make it harder for individual companies to retain proprietary knowledge. View Details

Keywords: Clusters; Clustering; Competitiveness; Life Sciences; Telecommunications; Science-based; Research And Development; Industry Clusters; Research; Innovation Strategy; Innovation and Management; Geographic Location; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Denmark

Register to Read

October 2001
Case

TIGR and ILRI: Solving Problems with Genomics

By: Ray A. Goldberg and James M Beagle

Discusses nonprofit institutional leadership applying advances in genetic science to solve health and animal problems in industrial countries and the developing world. View Details

Keywords: Developing Countries and Economies; Health; Technological Innovation; Leading Change; Emerging Markets; Genetics; Non-Governmental Organizations; Technology Adoption; Biotechnology Industry

January 2011 (Revised July 2012)
Case

Arcadia Biosciences: Seeds of Change (Abridged)

By: Arthur A. Daemmrich

Arcadia Biosciences is seeking to introduce genetically modified rice to China that will lower farmers' costs and generate environmental benefits through reduced greenhouse gas emissions. The case describes challenges facing this small agricultural biotechnology... View Details

Keywords: Plant-Based Agribusiness; Intellectual Property; Genetics; Environmental Sustainability; Science-Based Business; Climate Change; Agriculture and Agribusiness Industry; Biotechnology Industry; China

May 2016
Case

AbbVie

By: Kevin Schulman, Laura Little, Samyukta Mullangi and Stephen Schleicher

This case focuses on the impact of a novel regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging biosimilars... View Details

Keywords: Pharmaceutical Company; M＆A Valuation; AbbVie; Health Care; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry; United States

June 2003 (Revised March 2008)
Case

Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene

By: Regina E. Herzlinger and Marc Aquino

Personalized medicine requires the identification of mutated genes. Schering-Plough's search for the one related to asthma requires finding families with the disease. Examines the industry that helps conduct such research, including contract research organizations. View Details

Keywords: Health Disorders; Research and Development; Genetics; Biotechnology Industry; Biotechnology Industry

01 Nov 2024
In Practice

Layoffs Surging in a Strong Economy? Advice for Navigating Uncertain Times

Entrepreneurs coming from high-tech sectors such as biotechnology or medical devices may face unique challenges when starting a company after a layoff. These industries require significant upfront investment... View Details

Keywords: by Rachel Layne; Technology; Information Technology

January 2017
Case

Danaher Corporation, 2007–2017

By: John R. Wells and Gabriel Ellsworth

On July 2, 2016, Danaher Corporation completed the spinoff of Fortive Corporation. The previous day, Danaher’s stock price had reached an all-time high. In 2015, Danaher had decided to split off its test and measurement, fuel and fleet management, and automation... View Details